234 related articles for article (PubMed ID: 33445850)
41. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
Gustine JN; Meid K; Dubeau T; Severns P; Hunter ZR; Guang Y; Xu L; Treon SP; Castillo JJ
Am J Hematol; 2018 Aug; 93(4):511-517. PubMed ID: 29280186
[TBL] [Abstract][Full Text] [Related]
42. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
[TBL] [Abstract][Full Text] [Related]
43. Detection of the MYD88
Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
[TBL] [Abstract][Full Text] [Related]
44. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.
Papanota AM; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA; Gavriatopoulou M
J Blood Med; 2019; 10():291-300. PubMed ID: 31695539
[TBL] [Abstract][Full Text] [Related]
45. Preclinical models of Waldenström's macroglobulinemia and drug resistance.
Ailawadhi S; Paulus A; Chanan-Khan A
Best Pract Res Clin Haematol; 2016 Jun; 29(2):169-178. PubMed ID: 27825463
[TBL] [Abstract][Full Text] [Related]
46. Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation.
Migkou M; Fotiou D; Gavriatopoulou M; Dimopoulos MA
Expert Opin Drug Saf; 2021 Sep; 20(9):987-995. PubMed ID: 34137347
[No Abstract] [Full Text] [Related]
47. The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.
Chin CK; Leslie C; Grove CS; Van Vliet C; Cheah CY
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937595
[TBL] [Abstract][Full Text] [Related]
48. Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.
Riva E; Duarte PJ; Valcárcel B; Remaggi G; Murrieta I; Corzo A; Del Carpio D; Peña C; Vásquez J; Bove V; Teixeira L; Fleury-Perini G; Yantorno S; Samánez C; Lopresti S; Altamirano M; Villela L; Ruiz-Arguelles GJ; Ruiz-Delgado GJ; Montaño E; Verri V; Zamora Pérez E; Pérez Jacobo F; Idrobo H; Martínez-Cordero H; Beltran BE; Ramírez J; Castillo JJ; Malpica Castillo LE
JCO Glob Oncol; 2022 Aug; 8():e2100380. PubMed ID: 35939775
[TBL] [Abstract][Full Text] [Related]
49. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
50. [The efficacy and safety of Bruton tyrosine kinase inhibitors as monotherapy in the treatment of newly diagnosed patients with Waldenström macroglobulinemia].
Tao Y; Xu YL; Wang S; Wang L; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):490-494. PubMed ID: 37550205
[No Abstract] [Full Text] [Related]
51. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
52. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
[TBL] [Abstract][Full Text] [Related]
53. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.
Izutsu K; Kato H; Sekiguchi N; Fujisaki T; Kawakita T; Obara N; Matsue K; Nishimoto M; Hatayama T; Inagaki M; Fujikawa E
Int J Hematol; 2024 Apr; ():. PubMed ID: 38597986
[TBL] [Abstract][Full Text] [Related]
54. Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China.
Cao XX; Yi SH; Jiang ZX; He JS; Yang W; Du J; Sun CY; Wu Y; Chen WM; Liu XJ; Li BZ; Li CR; Sang W; Liu QH; Chu XX; Li F; Bai O; Mao M; Fu R; Wang W; Liu LH; Wang LQ; Dong YJ; Luo J; Li ZL; Wei YQ; Zhang QK; Liu J; Ding KY; Zou L; Chen BY; Hua LM; Jing HM; He J; Wang L; Li J; Qiu LG
Leuk Lymphoma; 2021 Nov; 62(11):2657-2664. PubMed ID: 34105439
[TBL] [Abstract][Full Text] [Related]
55. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512
[TBL] [Abstract][Full Text] [Related]
56. Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Advani P; Paulus A; Ailawadhi S
Hematol Oncol Stem Cell Ther; 2019 Dec; 12(4):179-188. PubMed ID: 31158330
[TBL] [Abstract][Full Text] [Related]
57. [MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].
Izumi S; Kimura K; Takeda Y; Tsukamoto S; Yamazaki M; Mishina T; Nagai Y; Takaishi K; Nagao Y; Oshima-Hasegawa N; Mitsukawa S; Mimura N; Takeuchi M; Ohwada C; Iseki T; Ota S; Nakaseko C; Sakaida E
Rinsho Ketsueki; 2018; 59(12):2600-2605. PubMed ID: 30626796
[TBL] [Abstract][Full Text] [Related]
58. Current and novel BTK inhibitors in Waldenström's macroglobulinemia.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Fotiou D; Dimopoulos MA
Ther Adv Hematol; 2021; 12():2040620721989586. PubMed ID: 33613931
[TBL] [Abstract][Full Text] [Related]
59. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate
Trotman J; Buske C; Tedeschi A; Matous JV; MacDonald D; Tam CS; Tournilhac O; Ma S; Treon SP; Oriol A; Ping J; Briso EM; Arango-Hisijara I; Dimopoulos MA
Clin Cancer Res; 2021 Nov; 27(21):5793-5800. PubMed ID: 34380643
[TBL] [Abstract][Full Text] [Related]
60. Emerging drugs for the treatment of Waldenström macroglobulinemia.
Despina F; Meletios Athanasios D; Efstathios K
Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
